Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Eli Lilly & Co.’s shares saw the biggest one-day drop since 2008 after CVS Health Corp. announced a plan to drop its ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...